OncoSec Medical Inc., a company developing intratumoral cancer immunotherapies, announced it has appointed Kellie Malloy Foerter as its new chief clinical development officer.
Malloy Foerter will be responsible for leading the company’s clinical drug developments.
“I am delighted to welcome Kellie to the OncoSec team, as I know firsthand the rigor and creativity she brings with respect to clinical trial design, execution and analysis. I have no doubt she will an invaluable resource to the company as we continue to advance our clinical development pipeline, including both KEYNOTE-695 and  KEYNOTE-890,” Daniel J. O’Connor, CEO and president of OncoSec, said.
Malloy Foerter, who has more than three decades of experience in clinical research, was previously at Syneos Health as executive vice president and general manager, clinical solutions. Before that, she spent 20 years at inVentiv Health.
